The historical development of neuromuscular blockade and its reversal traces back to the use of natural toxins by indigenous peoples in the Amazon basin during the 16th century. Early European explorers observed these people using curare, a plant-based toxin from Chondrodendron tomentosum, applied to arrows to paralyze and hunt animals. The active compound in curare, tubocurarine, later became the foundation for early neuromuscular blocking agents. It wasn’t until 1914 that the physiological mechanisms of neuromuscular transmission were better understood, thanks to Sir Henry Dale, who demonstrated that acetylcholine (ACh) was the neurotransmitter responsible for signal transmission at the neuromuscular junction (NMJ).
In the early 20th century, curare derivatives were first used in experimental physiology, paving the way for their application in clinical anesthesia. In 1942, Harold Griffith and Enid Johnson introduced curare into clinical practice, recognizing its potential to relax muscles without the need for deep general anesthesia. This revolutionized surgery by allowing more precise control over muscle relaxation.
The quest for effective reversal agents began alongside the use of curare. Early research by physiologist Pal in Vienna in 1900 showed that physostigmine, a cholinesterase inhibitor, could counteract the effects of curare in paralyzed dogs. This discovery opened the door to using cholinesterase inhibitors to reverse neuromuscular blockade. By the mid-1950s, neostigmine, a synthetic cholinesterase inhibitor, became widely used in anesthesia, especially in the "Liverpool anesthetic technique," to routinely reverse muscle paralysis at the end of surgery.
Despite the widespread use of cholinesterase inhibitors like neostigmine, there were still challenges, including delayed onset, incomplete reversal, and unwanted side effects. This drove the search for better reversal agents, leading to the development of sugammadex in the early 21st century. Sugammadex represented a significant advancement, offering a faster, more reliable way to reverse rocuronium and vecuronium-induced paralysis. This innovation has dramatically improved the safety and management of neuromuscular blockade, particularly in complex or high-risk surgeries.
